Quest Diagnostics (FRA:QDI) Momentum Rank: 3 (As of Sep. 22, 2026) — 63% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:QDI Quest Diagnostics Inc FRA:QDI
74 GF Score
Price €213.70
GF Value €165.38
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Quest Diagnostics Momentum Rank?

Quest Diagnostics FRA:QDI +0.14% 74 Momentum Rank is 3 as of Sep. 22, 2026, which is 63% below its 10-year median of 8.00. GuruFocus rates FRA:QDI with a GF Score™ of 74/100 and a GF Value™ of €165.38 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Quest Diagnostics has the Momentum Rank of 3.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Quest Diagnostics Momentum Rank Related Terms

FRA:QDI vs LH, MTD, GH: Momentum Rank Comparison

For the Diagnostics & Research subindustry, Quest Diagnostics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quest Diagnostics Momentum Rank vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Quest Diagnostics's Momentum Rank falls into.


FRA:QDI
74GF Score
Quest Diagnostics Inc FRA:QDI
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 3 mean?
Quest Diagnostics (FRA:QDI) has a Momentum Rank of 3 as of Sep. 22, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Quest Diagnostics and its competitors. This is 63% below median its historical median of 8.00. Over the past decade, Quest Diagnostics' Momentum Rank has ranged from 1.00 to 10.00.
Is Quest Diagnostics' Momentum Rank too high?
Quest Diagnostics' current Momentum Rank of 3 is 63% below median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Quest Diagnostics has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Quest Diagnostics' Momentum Rank compare to LH and MTD?
Quest Diagnostics' Momentum Rank of 3 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Quest Diagnostics' own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Medical Diagnostics & Research company?
A good Momentum Rank depends on the Medical Diagnostics & Research industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Quest Diagnostics and its competitors. Quest Diagnostics's current Momentum Rank is 3, which is 63% below median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Quest Diagnostics (FRA:QDI) is currently considered Modestly Overvalued. The stock's GF Value™ is €165.38, compared to a current price of €213.70 — trading 29.2% above its estimated fair value. The current Momentum Rank is 3, which is 63% below median its 10-year median of 8.00. Quest Diagnostics' overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Quest Diagnostics (FRA:QDI), the current Momentum Rank is 3 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Quest Diagnostics (FRA:QDI) Overvalued in 2026?

Based on GuruFocus' analysis, Quest Diagnostics stock appears to be overvalued. The current stock price of €213.70 is trading 29.2% above its estimated GF Value™ of €165.38. GuruFocus considers Quest Diagnostics to be Modestly Overvalued.

Key valuation signals for FRA:QDI:

  • Momentum Rank: 3 (63% below median its 10-year median of 8.00)
  • GF Value™: €165.38 vs. price of €213.70 (29.2% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the FRA:QDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Quest Diagnostics Business Description

Address 500 Plaza Drive, Secaucus, NJ, USA, 07094
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
74GF Score

Get the complete analysis for FRA:QDI

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€213.70
Price
€165.38
GF Value